GSA Capital Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

GSA Capital Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,258	Closed	-$281K	–	1914
2022 Q1	$281K	Sell	17,258 -4,777	-22%	-$74.8K	0.04%	940
2021 Q4	$359K	Sell	22,035 -57,110	-72%	-$963K	0.05%	812
2021 Q3	$1.18M	Buy	+79,145	New	+$1.27M	0.12%	230
2019 Q4	–	Sell	-7,199	Closed	-$478K	–	1808
2019 Q3	$478K	Buy	+7,199	New	+$483K	0.06%	583
2017 Q4	–	Sell	-12,596	Closed	-$731K	–	1884
2017 Q3	$731K	Buy	+12,596	New	+$1.36M	0.05%	714
2015 Q4	–	Sell	-4,265	Closed	-$707K	–	2016
2015 Q3	$707K	Buy	4,265 +3,190	+297%	+$702K	0.03%	897
2015 Q2	$259K	Buy	+1,075	New	+$286K	0.01%	1688
2014 Q4	–	Sell	-19,412	Closed	-$4.59M	–	1946
2014 Q3	$4.59M	Buy	19,412 +15,797	+437%	+$4.03M	0.24%	72
2014 Q2	$855K	Buy	3,615 +81	+2%	+$21.3K	0.04%	770
2014 Q1	$1.17M	Buy	+3,534	New	+$1.19M	0.08%	264

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

GSA Capital Partners's ICPT Position: Q2 2022 in Review

GSA Capital Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2022, closing a stake of 17,258 shares — an estimated $281K sold.

GSA Capital Partners first reported a position in ICPT in Q1 2014 and held it in 10 quarters. The position peaked at $4.59M in Q3 2014. 144 funds tracked by Wall St. Rank hold ICPT as of Q2 2022.

GSA Capital Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
GSA Capital Partners sold 17,258 Intercept Pharmaceuticals, Inc. shares in Q2 2022, an estimated $281K.
GSA Capital Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 10 quarters.
GSA Capital Partners's Intercept Pharmaceuticals, Inc. position peaked at $4.59M in Q3 2014.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2022.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.